Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network

加拿大癌症试验组PI = Dancey，Janet 美国国家临床试验网络-加拿大合作#CA180863 临床试验网络 行政管理2022年3月1日至2023年2月28日 总结 癌症生物学和技术的变革性进展，以表征癌症， 分子水平，再加上新药和细胞疗法的迅速发展， 要求对临床试验设计和交付进行根本性的重新评估， 患者和社会效益。加拿大癌症试验组（CCTG）与 与NCTN内部的美国调查人员和团体合作，强调国际合作 进行明确的实践改变试验，在罕见癌症环境中进行试验， 精准医疗战略加拿大临床试验合作网络（CCCTN） 作为NCTN，CCTG通过以下方式扩展了NCTN的科学专业知识：1）让最优秀和最聪明的人参与进来 在NCTN领导角色的网络中; 2）通过其 国家网络，包括加拿大的所有中心;以及3）便利加拿大的访问 这对于在罕见人群中测试干预措施的试验尤为重要。 CCTG致力于科学概念的发展、应计、生物标本的收集， 网络领导力，并在试验实施的工具部分（包括 信息技术和法规）。CCTG开发并参与NCTN成人癌症 乳腺、肺、泌尿系统和胃肠道恶性肿瘤的试验组合，在不常见/罕见 未满足需求的情况，如血液、皮肤、脑和头颈部癌症，以及 包括AYA试验中的青少年和年轻人。此外，CCTG还利用 有机会将其试验活动范围扩大到包括手术和生活方式干预 以及成像和数字健康端点。研究包括转化科学和其他 相关终点，以丰富来自NCTN试验和方法的信息， 技术开发，以改善临床试验设计、终点和执行。最后， 作为数据共享政策的一部分，CCTG贡献了来自NCTN试验的试验数据集。作为CCCTN， CCTG是加拿大最大、最有经验的临床试验单位， 从NCTN产生的战略加速科学进步转化为 癌症治疗的改进改善了儿童、青少年和成人的生活 被诊断为癌症

Canadian Cancer Trials Group PI = Dancey, Janet US National Clinical Trials Network – Canadian Collaborating #CA180863 Clinical Trials Network ADMINISTRATIVE SUPPLEMENT 1 March 2022 – 28 February 2023 Summary The transformational advances in cancer biology and technologies to characterize cancers at a molecular level, combined with the rapid expansion of novel drugs and cellular therapies, mandates a fundamental reevaluation of clinical trial design and delivery to ensure maximal patient and societal benefits. The Canadian Cancer Trials Group (CCTG) has strong partnerships with US investigators and groups within the NCTN, which emphasize international collaboration to conduct definitive practice-changing trials, trials in rare cancers settings, and trials testing precision-medicine strategies. As the Canadian Collaborating Clinical Trials Network (CCCTN) of the NCTN, CCTG expands NCTN’s scientific expertise by: 1) Involving the best and brightest within its network in NCTN leadership roles; 2) Increasing clinical trial capacity through its national network, which includes all centres in Canada; and, 3) Facilitates access to Canadian patients, which is particularly important for trials testing interventions in rare populations. CCTG contributes to scientific concept development, accrual, biospecimen collection, and network leadership, and has expertise in instrumental components of trial conduct (including information technology and regulations). CCTG develops and participates in NCTN adult cancer trial portfolios in breast, lung, urological, and gastrointestinal malignancies, in uncommon/rare settings of unmet need such as hematological, skin, brain and head and neck cancers, and includes adolescents and young adults on AYA trials. In addition, CCTG capitalizes on opportunities to extend its scope of trial activity to include surgical and lifestyle interventions and imaging and digital health endpoints. Research incorporates translational science and other correlative endpoints to enrich information derived from NCTN trials and methods and technology development to improve clinical trial designs, endpoints, and execution. Finally, CCTG contributes trial datasets from NCTN trials as part of its data sharing policy. As the CCCTN, CCTG, Canada’s largest and most experienced clinical trials unit, creates and delivers innovative strategies that arise from the NCTN accelerating the translation of scientific advances into improvements in cancer treatments improving the lives of children, adolescents, and adults diagnosed with cancer.